What is the translation of " PROGRAF " in Croatian? S

Noun
prografa
prografom

Examples of using Prograf in English and their translations into Croatian

{-}
  • Colloquial category close
  • Ecclesiastic category close
  • Computer category close
Advagraf and Prograf are not interchangeable.
Advagraf se ne može zamijeniti Prografom i obrnuto.
Month graft survival was 96.7% for Advagraf,92.9% for Prograf and 95.7% for ciclosporin.
Dvanaestomjesečno preživljenje presatka iznosilo je 96,7% za Advagraf,92,9% za Prograf i 95,7% za ciklosporin.
Dr. Parker, get a prograf and a CMP and keep Dr. Pierce updated.
Dr. Parker, uradite prograf i CMP i obavjestite dr. Pirsa.
Patients were either switched to treatment with Envarsus once daily or continued Prograf treatment twice daily.
Bolesnici su prebačeni na liječenje Envarsusom jednom dnevno ili su nastavili s liječenjem Prografom dvaput dnevno.
Prograf and Advagraf both contain the active substance, tacrolimus.
Djelatna tvar i u Prografu i u Advagrafu je takrolimus.
Conversion between Modigraf and Prograf tacrolimus formulations.
Prelazak između Modigrafa i Prografa kao formulacija takrolimusa.
Treatment failure occurred in 18.3% patients treated with Envarsus(49 out of 268), and19.6% given Prograf 54 out of 275.
Liječenje je bilo neuspješno kod 18, 3% bolesnika liječenih Envarsusom(49 od 268) i 19,6% bolesnika liječenih Prografom 54 od 275.
Example: Total daily dose Prograf capsules given as 1 mg in the morning and 0.5 mg in the evening.
Primjer: ukupna dnevna doza Prograf kapsula daje se kao 1 mg ujutro i 0, 5 mg navečer.
Treatment emergent fatal adverse events occurred in 1.2% of Envarsus patients and 0.6% of Prograf patients.
Štetni događaji sa smrtnim ishodom tijekom liječenja dogodili su se u 1,2% bolesnika koji su uzimali Envarsus i u 0,6% bolesnika koji su uzimali Prograf.
Envarsus has been shown to be at least as effective as Prograf in two main studies in patients with kidney transplants.
Envarsus je dokazano barem jednako učinkovit kao Prograf prema dvije glavne studije provedene na bolesnicima s presađenim bubrezima.
The relationship between tacrolimus trough levels(C24) and systemic exposure(AUC 0-24) is similar between the two formulations Advagraf and Prograf.
Dvije formulacije takrolimusa, Advagraf i Prograf, imaju sličan odnos između najnižih izmjerenih koncentracija(C24) i sistemske izloženosti AUC 0-24.
The second study compared Envarsus with Prograf as part of standard treatment in 543 patients with a newly transplanted kidney.
U drugoj studiji napravljena je usporedba Envarsusa s Prografom kao dijelom standardnog liječenja 543 bolesnika s novopresađenim bubrezima.
The dose recommendations for lung, pancreas andintestinal transplantation are based on limited prospective clinical trial data with the Prograf formulation.
Preporuke za doze kod transplantacije pluća, gušterače icrijeva temelje se na ograničenim podacima iz prospektivnih kliničkih ispitivanja formulacije Prograf.
These studies compared Envarsus with Prograf, a widely used and well-established tacrolimus medicine that releases tacrolimus more quickly.
Studije uspoređuju Envarsus s Prografom, široko korištenim i dobro utvrđenim lijekom s akrolimusom koji takrolimus otpušta brže.
The relationship between tacrolimus trough levels(C12) and systemic exposure(AUC0-12)is similar between the 2 formulations Modigraf granules and Prograf capsules.
Odnos između najnižih razina takrolimusa(C12) i sistemske izloženosti(AUC0-12)sličan je za obje formulacije takrolimusa, Modigraf granule i Prograf kapsule.
The efficacy and safety of Advagraf and Prograf, both in combination with mycophenolate mofetil(MMF) and corticosteroids, was compared in 667 de novo kidney transplant recipients.
Djelotvornost i sigurnost primjene Advagrafa i Prografa, oba u kombinaciji s mikofenolat mofetilom(MMF) i kortikosteroidima, uspoređivala se u 667 de novo primatelja presatka bubrega.
In healthy subjects the systemic exposure to tacrolimus(AUC)for Modigraf was approximately 18% higher than that for Prograf capsules when administered as single doses.
U zdravih je ispitanika sistemska izloženost takrolimusu(AUC)za Modigraf iznosila približno 18% više nego za Prograf kapsule kad su se primijenjeni kao jednokratne doze.
Similarly, for conversion of patients from Prograf capsules to Modigraf granules, the total daily Modigraf dose should preferably be equal to the total daily Prograf dose.
Slično tome, za prebacivanje bolesnika s Prograf kapsula na Modigraf granule ukupna dnevna doza Modigrafa treba po mogućnosti biti jednaka ukupnoj dnevnoj dozi Prografa..
Results of a single dose bioequivalence study with adult healthy volunteers showed that Modigraf granules were approximately 20% more bioavailable than the Prograf capsules.
Rezultati ispitivanja bioekvivalencije s jednom dozom u odraslih zdravih dobrovoljaca pokazali su da Modigraf granule imaju približno 20% veću bioraspoloživost nego Prograf kapsule.
The efficacy and safety of Envarsus and Prograf, both in combination with mycophenolate mofetil(MMF) or mycophenolate sodium(MPS) and corticosteroids, was compared in 324 stable kidney transplant recipients.
Djelotvornost i sigurnost Envarsusa i Prografa, oba u kombinaciji s mikofenolat mofetilom ili mikofenolatnatrijem i kortikosteroidima, uspoređena je u 324 stabilna primatelja presatka bubrega.
The event rate for centrally-read, biopsy-confirmed acute rejection(BPAR)during the 360-day study was 13.1% in the Envarsus group(N=268) and 13.5% in the Prograf group N=275.
Stopa centralno interpretiranog akutnog odbacivanja presatka potvrđenog biopsijom(BPAR)tijekom 360 dana ispitivanja bila je 13,1% u Envarsus skupini(N 268), a 13,5% u Prograf skupini N 275.
The efficacy and safety of Prograf, ciclosporin and Advagraf, all in combination with basiliximab antibody induction, MMF and corticosteroids, was compared in 638 de novo kidney transplant recipients.
Djelotvornost i sigurnost primjene Prografa, ciklosporina i Advagrafa, svih u kombinaciji s indukcijom baziliksimab protutijelima, MMF-om i kortikosteroidima, uspoređivala se u 638 de novo primatelja presatka bubrega.
The Agency's Committee for Medicinal Products for Human Use(CHMP) decided that the approved doses of Envarsus have been shown to have a comparable quality, safety andeffectiveness to Advagraf and Prograf.
Povjerenstvo Agencije za humane lijekove(CHMP) odlučilo je da odobrena doza Envarsus-a posjeduje kvalitetu, sigurnost idjelotvornost usporedive s Advagraf-om i Prograf-om.
In stable patients converted from Prograf capsules(twice daily) to Advagraf(once daily) on a 1:1(mg: mg) total daily dose basis, the systemic exposure to tacrolimus(AUC0-24)for Advagraf was approximately 10% lower than that for Prograf.
U stabilnih bolesnika koji su prešli s kapsula Prografa(dvaput na dan) na kapsule Advagrafa(jedanput na dan) u omjeru ukupne dnevne doze 1:1(mg: mg), sistemska izloženost takrolimusu(AUC0-24)bila je oko 10% niža za Advagraf od one za Prograf.
There appears to be no significant difference in the pattern of adverse events suspected to be causally related to study drug between once daily Envarsus andtacrolimus immediate-release capsules Prograf.
Čini se da nema značajne razlike u uzorku nuspojava za koje se sumnja da su uzročno povezane s ispitivanim lijekom, između Envarsusa primijenjenog jedanput na dan ikapsula takrolimusa s trenutnim oslobađanjem Prograf.
The event rate for locally read biopsy-confirmed acute rejection(BPAR) during the 360 day study was 1.2% in the Envarsus group(N=162) post conversion from Prograf at a dose ratio of 1:0.7(mg: mg) and1.2% in the group maintained on Prograf N=162.
Stopa lokalno interpretirane akutne reakcije odbacivanja potvrđene biopsijom(BPAR), tijekom 360 dana ispitivanja iznosila je 1,2% u skupini koja je primala Envarsus(N=162) nakon prebacivanja s Prografa u omjeru doza od 1: 0,7(mg: mg) i1,2% u skupini koja je zadržana na Prografu N=162.
The efficacy and safety of Envarsus and Prograf, both in combination with Mycophenolate Mofetil(MMF) corticosteroids, and IL-2 receptor antagonist as per the standard of care was compared in a randomised, double-blind, double-dummy study, in 543 de novo kidney transplant recipients.
Djelotvornost i sigurnost Envarsusa i Prografa, oba u kombinaciji s mikofenolat mofetilom, kortikosteroidima, i antagonistima receptora za IL-2 prema standardima njege, uspoređena je u randomiziranom, dvostruko slijepom ispitivanju s dvostrukim placebom s 543 bolesnika s de novo transplantiranim bubrezima.
The efficacy failure rate as measured by the composite endpoint of death, graft loss, locally read BPAR andloss to follow-up was 2.5% in both the Envarsus and Prograf groups.
Stopa neuspjeha djelotvornosti izmjerena prema kompozitnom ishodu koji obuhvaća ishod smrti, gubitak presatka, lokalno interpretirani BPAR i gubitak u praćenju iznosila je2,5% u obje skupine, u onoj koja je primala Envarsus i u onoj koja je primala Prograf.
The 12-month patient survival rates were 98.6% for Advagraf,95.7% for Prograf and 97.6% for ciclosporin; in the Advagraf arm 3 patients died(all male), in the Prograf arm 10 patients died(3 female, 7 male) and in the ciclosporin arm 6 patients died 3 female, 3 male.
Dvanaestomjesečna stopa preživljenja bolesnika iznosila je 98,6% za Advagraf,95,7% za Prograf i 97,6% za ciklosporin; u skupini koja je primala Advagraf umrlo je 3 bolesnika(svi muškarci), u skupini koja je primala Prograf umrlo je 10 bolesnika(3 žene, 7 muškaraca) i u skupini koja je primala ciklosporin umrlo je 6 bolesnika 3 žene, 3 muškarca.
Higher Cavg(~50%), reduced peak trough fluctuation(Cmax/Cmin) and a longer Tmax were seen for Envarsus when compared with both,tacrolimus immediate-release formulation(Prograf) and a tacrolimus once daily formulation Advagraf.
Viša Cavg(~50%), smanjena fluktuacija vršne i najniže koncentracije(Cmax/Cmin) te dulji Tmax uočeni su za Envarsus u usporedbi s oba takrolimusa:s trenutnim oslobađanjem(Prograf) i takrolimusom koji se uzima jedanput na dan Advagraf.
Results: 37, Time: 0.0341
S

Synonyms for Prograf

Top dictionary queries

English - Croatian